Toga-Sato, Shiori
Tosaki, Takahiro
Kondo, Masaki
Tsunekawa, Shin
Kato, Yoshiro
Nakamura, Jiro
Kamiya, Hideki
Article History
Received: 18 October 2020
Accepted: 9 December 2020
First Online: 2 January 2021
Change Date: 27 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13340-021-00491-9
Compliance with ethical standards
:
: Shiori Toga-Sato declares no conflicts of interest associated with this manuscript. Takahiro Tosaki received lecture fees from Eli Lilly, Astellas, AstraZeneca, Mitsubishi Tanabe, MSD and Takeda, and research funding from Mitsubishi Tanabe, Daiichi Sankyo and Takeda. Masaki Kondo received research funding from Johnson & Johnson, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Taisho Toyama, MSD, Mitsubishi Tanabe, Sanofi, Takeda, Japan Tobacco, Novo Nordisk and Ono. Shin Tsunekawa received research funding from Johnson & Johnson, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Taisho Toyama, MSD, Mitsubishi Tanabe, Sanofi, Takeda, Japan Tobacco, Novo Nordisk and Ono. Yoshiro Kato received research funding from Johnson & Johnson, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Taisho Toyama, MSD, Mitsubishi Tanabe, Sanofi, Takeda, Japan Tobacco, Novo Nordisk and Ono. Jiro Nakamura received lecture fees from Kyowa Hakko Kirin, Ono, Pfizer, Eli Lilly, Novartis, Sanofi, MSD, Taisho Toyama, Mitsubishi Tanabe, Astellas and Shionogi, and research funding from Johnson & Johnson, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Taisho Toyama, MSD, Mitsubishi Tanabe, Sanofi, Takeda, Japan Tobacco, Novo Nordisk and Ono. Hideki Kamiya received lecture fees from Eli Lilly, Ono, Novartis, Astellas, MSD, Takeda, AstraZeneca, Boehringer Ingelheim, Sanofi and Novo Nordisk, and research funding from Johnson & Johnson, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Taisho Toyama, MSD, Mitsubishi Tanabe, Sanofi, Takeda, Japan Tobacco, Novo Nordisk and Ono.